Skip to main content
. 2023 Nov 21;23:94–105. doi: 10.1016/j.ijpddr.2023.11.001

Table 2.

Faecal egg count reduction (FECR) (calculated using the EggCounts package in R Studio, assuming a common drug efficacy for all animals) and coproantigen reduction test (CRT) results for F. hepatica on all 12 farms included in the efficacy trial.

Farm Federal state Method Drug Product N total N paired FEC n FECR % 2.5% CL 97.5% CL N paired cELISA cELISA positive before/afterd
1aa Lower Saxony Mod. FLUKEFINDER® ABZ Valbazen 1.9% 13 13 4 94.92 90.51 97.73 13 3/1
1 bb Lower Saxony Mod. FLUKEFINDER® ABZ Valbazen 1.9% 13 4 4 99.87 98.15 100 4 3/0
2aa Mecklenburg-Western Pomerania Mod. FLUKEFINDER® TCBZ Cydectin TriclaMox 46 43 35 98.4 98.07 98.69 44 35/1
2 bb Mecklenburg-Western Pomerania Mod. FLUKEFINDER® TCBZ Cydectin TriclaMox 46 41 33 99.94 99.85 99.99 n.d n.d.
3 Schleswig-Holstein Mod. FLUKEFINDER® TCBZ Cydectin TriclaMox 79 71 3 99.81 97.12 100 4 3/0
4 North Rhine Westphalia FLUKEFINDER® TCBZ Endofluke 55 46 8 83.42 80.73 86.11 49 9/0
5 Brandenburg FLUKEFINDER® TCBZ Endofluke 32 32 12 99.41 98.54 99.82 32 12/0
6aa Lower Saxony FLUKEFINDER® TCBZ Endofluke 53 36 24 0.01 0 0.11 37 30/33
6 bc Lower Saxony FLUKEFINDER® TCBZ Cydectin TriclaMox 53 27 22 0 0 0.06 29 27/27
7 North Rhine-Westphalia FLUKEFINDER® TCBZ Endofluke 48 43 28 99.55 99.39 99.69 45 33/0
8 Baden-Wuerttemberg FLUKEFINDER® TCBZ Endofluke 30 30 30 99.71 99.64 99.77 30 30/0
9 Schleswig-Holstein FLUKEFINDER® TCBZ Cydectin TriclaMox 21 13 7 99.92 98.82 100 13 5/0
10 North Rhine-Westphalia FLUKEFINDER® TCBZ Cydectin TriclaMox 17 17 8 99.98 99.93 100 17 9/0
11 Brandenburg FLUKEFINDER® TCBZ Endofluke 9 9 5 99.82 97.34 100 9 4/0
12 Lower Saxony FLUKEFINDER® TCBZ Endofluke 27 27 13 99.96 99.35 100 27 12/0

N total, total number of coproscopically examined individual animals on the farm before flukicidal treatment; N paired, total number of paired samples pre and post treatment; n, number of coproscopically F. hepatica-positive animals before treatment; CL, credibility limit; ABZ, albendazole; TCBZ, triclabendazole.

a

FECR/coproantigen reduction from day 0 to day 14 (1a and 6a)/to day 15 (2a).

b

FECR/coproantigen reduction from day 0 to day 21 (1 b)/to day 28 (2 b).

c

FECR/coproantigen reduction from day 21 to day 35 after treatment with the double dose of TCBZ on day 21.

d

Number of samples positive in the coproantigen ELISA before/after treatment using the 2% of the positive control threshold.